Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 5:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–3 of 3 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: IDH1-mutant Cholangiocarcinoma Clear all

Terminated Phase 1Phase 2 Interventional Results available

Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma

NCT05921760

View directory record Official record

Conditions: IDH1-mutant Cholangiocarcinoma
Interventions: Ivosidenib, Nivolumab, Ipilimumab; Drug
Lead sponsor: Servier Bio-Innovation LLC; Industry
Eligibility: 18 Years and older

Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 4
States / cities: San Francisco, California • Baltimore, Maryland • Boston, Massachusetts

Source: ClinicalTrials.gov public record

Updated Apr 19, 2026 · Synced May 21, 2026, 5:56 PM EDT

Active, not recruiting Phase 2 Interventional Results available

Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors

NCT03878095

View directory record Official record

Conditions: Malignant Solid Neoplasm, Refractory Cholangiocarcinoma, Refractory Malignant Solid Neoplasm
Interventions: Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Ceralasertib, Computed Tomography, Magnetic Resonance Imaging, Olaparib; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older

Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 13
States / cities: Birmingham, Alabama • New Haven, Connecticut • Trumbull, Connecticut + 9 more

Source: ClinicalTrials.gov public record

Updated Apr 28, 2026 · Synced May 21, 2026, 5:56 PM EDT

Active, not recruiting Phase 2 Interventional

Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

NCT03212274

View directory record Official record

Conditions: Advanced Malignant Solid Neoplasm, Glioblastoma, Recurrent Cholangiocarcinoma, Recurrent Glioma, Recurrent Malignant Solid Neoplasm, WHO Grade 2 Glioma, WHO Grade 3 Glioma
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older

Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 51
States / cities: Costa Mesa, California • Los Angeles, California • Newport Beach, California + 36 more

Source: ClinicalTrials.gov public record

Updated Feb 18, 2026 · Synced May 21, 2026, 5:56 PM EDT